Number of the records: 1  

Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway

  1. TitleDevelopment of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway
    Author Kočibálová Zuzana 1993-    SCOPUS
    Co-authors Guzyová Martina 1989-

    Borovská Ivana 1993- SAVMOFYZ - Ústav molekulárnej fyziológie a genetiky SAV    ORCID

    Messingerová Lucia 1985- SAVMOFYZ - Ústav molekulárnej fyziológie a genetiky SAV    SCOPUS    ORCID

    Copáková Lucia

    Sulová Zdena 1957- SAVMOFYZ - Ústav molekulárnej fyziológie a genetiky SAV    SCOPUS    ORCID

    Breier Albert 1957-    SCOPUS    RID    ORCID

    Source document Cancers. Vol. 13, no. 14 (2021), art. no. 3629
    Languageeng - English
    CountryCH - Switzerland
    Document kindrozpis článkov z periodík (rbx)
    CitationsBAILLY, Christian - THURU, Xavier - QUESNEL, Bruno. Modulation of the Gal-9/TIM-3 Immune Checkpoint with alpha-Lactose. Does Anomery of Lactose Matter? In CANCERS, 2021, vol. 13, no. 24, pp. Dostupné na: https://doi.org/10.3390/cancers13246365.
    JOSE LADERACH, Diego - COMPAGNO, Daniel. Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure. In CANCERS, 2021, vol. 13, no. 18, pp. Dostupné na: https://doi.org/10.3390/cancers13184529.
    SHI, Yuanwei - TANG, Danting - LI, Xiaoqi - XIE, Xiaoli - YE, Yufu - WANG, Lijuan. Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy? In FRONTIERS IN ONCOLOGY, 2022, vol. 12, no., pp. ISSN 2234-943X. Dostupné na: https://doi.org/10.3389/fonc.2022.889034.
    MAJERNIK, Martin - JENDZELOVSKY, Rastislav - VARGOVA, Jana - JENDZELOVSKA, Zuzana - FEDOROCKO, Peter. Multifunctional Nanoplatforms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer. In PHARMACEUTICS, 2022, vol. 14, no. 5, pp. Dostupné na: https://doi.org/10.3390/pharmaceutics14051075.
    PENG, X.H. - ZHU, X.F. - DI, T.N. - TANG, F.T. - GUO, X.J. - LIU, Y. - BAI, J. - LI, Y.H. - LI, L.J. - ZHANG, L.S. The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification. In FRONTIERS IN IMMUNOLOGY. ISSN 1664-3224, SEP 23 2022, vol. 13. Dostupné na: https://doi.org/10.3389/fimmu.2022.994053.
    BAILLY, C. - THURU, X. - GOOSSENS, L. - GOOSSENS, J.F. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. In BIOCHEMICAL PHARMACOLOGY. ISSN 0006-2952, MAR 2023, vol. 209. Dostupné na: https://doi.org/10.1016/j.bcp.2023.115445.
    LV, Y. - MA, X. - MA, Y.X. - DU, Y.X. - FENG, J.F. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). In GENES & DISEASES. ISSN 2352-4820, NOV 2023, vol. 10, no. 6, p. 2366-2382. Dostupné na: https://doi.org/10.1016/j.gendis.2022.05.020.
    SHAO, Y. - GUI, X.R. - WANG, Y.X. - SHENG, L. - SUN, D. - ZENG, Q.D. - WANG, H.Y. Serum soluble immune checkpoint levels predict cervical lymph node metastasis of differentiated thyroid carcinoma patients. In CANCER MEDICINE. ISSN 2045-7634, SEP 2023, vol. 12, no. 17, p. 17648-17659. Dostupné na: https://doi.org/10.1002/cam4.6382.
    YILDIRIM, C. Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion. In MOLECULAR BIOLOGY REPORTS. ISSN 0301-4851, DEC 2024, vol. 51, no. 1. Dostupné na: https://doi.org/10.1007/s11033-024-09563-w.
    CategoryADMA - Scientific papers in foreign impacted journals registered in Web of Sciences or Scopus
    Category of document (from 2022)V3 - Vedecký výstup publikačnej činnosti z časopisu
    Type of documentčlánok
    Year2021
    Registered inWOS
    Registered inSCOPUS
    DOI 10.3390/cancers13143629
    article

    article

    rokCCIFIF Q (best)JCR Av Jour IF PercSJRSJR Q (best)CiteScore
    N
    rok vydaniarok metrikyIFIF Q (best)SJRSJR Q (best)
    202120206.639Q11.818Q1
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.